Supplemental Table 4 Risk of specific cancer in patients using insulin glargine or other insulin analogues in comparison with those using human insulin (fixed analysis)

Full model[a]	Insulin glargine				Other insulin analogues				Human insulin
	IR	n	HR	95% CI	IR	n	HR	95% CI	IR
Colon cancer									
Full	1.65	13	0.61	0.43, 0.88	2.36	38	0.87	0.78, 0.97	2.83
Full model, adjusted for use of OGLD (time-dependent)									
Biguanide			0.74	0.64, 0.87			0.92	0.85, 0.99	
SU			0.74	0.64, 0.86			0.91	0.84, 0.99	
Other OGLD			0.74	0.64, 0.87			0.92	0.85, 0.99	
Full model + average DDD			0.64	0.45, 0.90			0.73	0.64, 0.84	
Full model, stratified for dose of first insulin prescription									
< Median		0	–			0	–		
Median		10	0.29	0.16, 0.53		29	0.70	0.60, 0.82	
> Median		3	–			9	0.76	0.58, 1.00	
Full model including a latency time of 1 year[b]	1.03	8	0.83	0.54, 1.28	0.94	15	0.88	0.77, 1.00	1.71
Bladder cancer									
Full	1.02	8	1.77	1.04, 3.00	0.93	15	0.69	0.57, 0.84	1.00
Full model, adjusted for use of OGLD (time-dependent)									
Biguanide			0.82	0.67, 1.01			0.84	0.75, 0.95	
SU			0.83	0.68, 1.01			0.84	0.75, 0.95	
Other OGLD			0.82	0.67, 1.01			0.84	0.74, 0.95	
Full model + average DDD			1.26	0.63, 2.49			0.61	0.47, 0.78	
Full model, stratified for dose of first insulin prescription									
< Median		0	–			0	–		
Median		7	2.26	1.17, 4.39		11	0.49	0.36, 0.66	
> Median		1	–			4	0.77	0.57, 1.02	
Full model including a latency time of 1 year[b]	0.64	5	2.06	0.83, 5.12	0.69	11	0.84	0.69, 1.02	0.74
Respiratory tract cancer									
Full	1.53	12	0.92	0.74, 1.16	2.11	34	0.70	0.62, 0.78	1.74
Full model, adjusted for use of OGLD (time-dependent)									
Biguanide			0.90	0.71, 1.13			0.86	0.78, 0.94	
SU			0.81	0.61, 1.06			0.85	0.78, 0.93	

		n				n			
Other OGLD			0.94	0.75, 1.19			0.85	0.78, 0.93	
Full model + average DDD			0.57	0.42, 0.79			0.70	0.62, 0.78	
Full model, stratified for dose of first insulin prescription									
< Median		0	–			1	–		
Median		8	0.72	0.44, 1.18		21	0.69	0.58, 0.82	
> Median		4	0.88	0.62, 1.24		12	0.83	0.73, 0.95	
Full model including a latency time of 1 year[b]	1.16	9	1.06	0.81, 1.39	1.25	20	0.77	0.68, 0.88	1.29
Prostate cancer									
Full	1.06	4	1.17	0.84, 1.62	1.26	10	0.82	0.69, 0.97	1.74
Full model, adjusted for use of OGLD (time-dependent)									
Biguanide			1.24	0.81, 1.57			0.82	0.69, 0.97	
SU			1.18	0.85, 1.63			0.76	0.63, 0.93	
Other OGLD			1.21	0.85, 1.73			0.51	0.37, 0.69	
Full model + average DDD			1.01	0.61, 1.67			0.98	0.81, 1.18	
Full model, stratified for dose of first insulin prescription									
< Median		0	–			0	–		
Median		3	0.96	0.57, 1.64		6	0.78	0.46, 1.31	
> Median		1	–			4	0.87	0.65, 1.16	
Full model including a latency time of 1 year[b]	0.76	3	2.19	1.03, 4.66	0.64	5	0.84	0.68, 1.03	1.28
Breast cancer									
Full	5.40	21	1.39	1.08, 1.79	2.81	23	1.00	0.93, 1.09	2.88
Full model, adjusted for use of OGLD (time-dependent)									
Biguanide			1.40	1.09, 1.79			1.00	0.92, 1.09	
SU			1.46	1.12, 1.90			1.01	0.93, 1.09	
Other OGLD			1.59	1.21, 2.08			1.03	0.94, 1.11	
Full model + average DDD			1.43	1.08, 1.88			0.94	0.86, 1.03	
Full model, stratified for dose of first insulin prescription									
< Median		1	–			2	–		
Median		13	1.49	1.12, 1.98		15	1.10	0.96, 1.26	
> Median		7	1.01	0.62, 1.63		6	0.28	0.11, 0.71	
Full model including a latency time of 1 year[b]	2.35	9	2.19	1.44, 3.33	1.48	12	1.01	0.92, 1.11	2.36

[a]In the full model, adjustments were made for age at first insulin prescription, sex, calendar time, number of unique drugs used in the year before start of insulin and number of hospitalisations in the year before start of insulin. Days of prior OGLD use, number of days of OGLD use as of January 1998.

[b]Model included a 1 year latency period: exposure was cumulated up till one year prior to the date of cancer diagnosis

n, number of events; SU, sulfonylurea derivative